NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
20
ADAP Quote, Financials, Valuation and Earnings
Last price:
$0.60
Seasonality move
:
36.97%
Day range:
$0.59 - $0.61
52-week range:
$0.47 - $2.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.85x
P/B ratio:
1.93x
Volume:
3.1M
Avg. volume:
2.7M
1-year change:
37.05%
Market cap:
$154.8M
Revenue:
$60.3M
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
VRNA
Verona Pharma PLC
|
$2M | -$0.41 | -- | -2.08% | $47.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.60 | $3.50 | $154.8M | -- | $0.00 | 0% | 0.85x |
|
AUTL
Autolus Therapeutics PLC
|
$2.29 | -- | $609.4M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$3.90 | -- | $2.3M | -- | $0.00 | 0% | 3.52x |
|
NCNA
NuCana PLC
|
$1.20 | -- | $4.7M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.67 | -- | $5.5M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$42.06 | $47.29 | $3.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
|
VRNA
Verona Pharma PLC
|
47.91% | -0.070 | 5.1% | 12.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
Adaptimmune Therapeutics PLC vs. Competitors
-
Which has Higher Returns ADAP or AUTL?
Autolus Therapeutics PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -522.15%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About ADAP or AUTL?
Adaptimmune Therapeutics PLC has a consensus price target of $3.50, signalling upside risk potential of 274.78%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 356.33%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC4 2 0 AUTLAutolus Therapeutics PLC7 2 0 -
Is ADAP or AUTL More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.863% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.984, suggesting its more volatile than the S&P 500 by 98.37%.
-
Which is a Better Dividend Stock ADAP or AUTL?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or AUTL?
Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.85x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns ADAP or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About ADAP or BDRX?
Adaptimmune Therapeutics PLC has a consensus price target of $3.50, signalling upside risk potential of 274.78%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 105.52%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC4 2 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is ADAP or BDRX More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.863% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock ADAP or BDRX?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or BDRX?
Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.85x versus 3.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M BDRXBiodexa Pharmaceuticals PLC3.52x -- -- --
-
Which has Higher Returns ADAP or NCNA?
NuCana PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About ADAP or NCNA?
Adaptimmune Therapeutics PLC has a consensus price target of $3.50, signalling upside risk potential of 274.78%. On the other hand NuCana PLC has an analysts' consensus of -- which suggests that it could grow by 4038.89%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC4 2 0 NCNANuCana PLC3 1 0 -
Is ADAP or NCNA More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.863% more volatile than S&P 500. In comparison NuCana PLC has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.593%.
-
Which is a Better Dividend Stock ADAP or NCNA?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or NCNA?
Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than NuCana PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is lower than NuCana PLC's net income of -$5.9M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.85x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns ADAP or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About ADAP or TCBP?
Adaptimmune Therapeutics PLC has a consensus price target of $3.50, signalling upside risk potential of 274.78%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 349.17%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC4 2 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is ADAP or TCBP More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.863% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADAP or TCBP?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or TCBP?
Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.85x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns ADAP or VRNA?
Verona Pharma PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -763.91%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Verona Pharma PLC's return on equity of -74.15%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M VRNAVerona Pharma PLC90.35% -$0.56 $250.5M -
What do Analysts Say About ADAP or VRNA?
Adaptimmune Therapeutics PLC has a consensus price target of $3.50, signalling upside risk potential of 274.78%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 12.42%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC4 2 0 VRNAVerona Pharma PLC5 0 0 -
Is ADAP or VRNA More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.863% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.579%.
-
Which is a Better Dividend Stock ADAP or VRNA?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or VRNA?
Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Verona Pharma PLC quarterly revenues of $5.6M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Verona Pharma PLC's net income of -$43M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.85x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M VRNAVerona Pharma PLC-- -- $5.6M -$43M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 2.15% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 10.25% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.43% over the past day.
